The objective of this study is to investigate the prognostic value of the percentage change of maximum standardized uptake value (ΔSUVmax) assessed by PET/CT scan after 2 cycles of chemotherapy (iPET2) in patients with classic Hodgkin's lymphoma (CHL). ΔSUVmax was calculated as follows: the ratio of (SUVmax at baseline-SUVmax at iPET2)/SUVmax at baseline which was determined before initiation of ABVD chemotherapy. The median ΔSUVmax of 46 patients at iPET2 was 87.9% (range - 6.1-100.0%). The optimal ΔSUVmax cutoff value for progression-free survival (PFS) was 83.0% with the receiver operating characteristic curve. The area under the curve for PFS was 0.886 (95% CI 0.788-0.984, p < 0.001). The median PFS of 29 (63.0%) patients who achieved a SUVmax reduction of more than 83.0% was 34 months. The median PFS of 17 (37.0%) patients with ΔSUVmax < 83.0% was 9 months. This difference was significant (p < 0.001). Cohen's kappa coefficient of Deauville Score (DS)- and ΔSUVmax-judged positivity was 0.752 (95% CI 0.592-0.992, p < 0.001), suggesting a strong consistency. Multivariate analysis showed that ΔSUVmax at iPET2 less than 83.0% of SUVmax at diagnosis was an independent factor predicting PFS [HR = 11.339, 95% CI 2.485-51.742, p = 0.002]. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of ΔSUVmax<83.0% was 84.6%, 81.8%, 67.7%, 93.1%, and 82.6%, which was similar to that of DS as 61.5%, 87.9%, 66.7%, 85.3%, and 80.4%, respectively. ΔSUVmax<83.0% of iPET2 effectively predicts prognosis of patients with CHL treated with ABVD.

中文翻译：

---

在经典霍奇金淋巴瘤患者化疗2个周期后，通过PET / CT扫描评估ΔSUVmax的预后意义。

这项研究的目的是调查经典霍奇金淋巴瘤（CHL）患者经过2疗程化疗（iPET2）后通过PET / CT扫描评估的最大标准化摄取值（ΔSUVmax）的百分比变化的预后价值。ΔSUVmax的计算如下：（ABSUVD化疗开始前确定的）（基线的SUVmax-iPET2的SUVmax）/基线的SUVmax之比。iPET2上46例患者的中位ΔSUVmax为87.9％（范围-6.1-100.0％）。对于无进展生存期（PFS）的最佳ΔSUVmax临界值与接收器工作特性曲线相符，为83.0％。PFS的曲线下面积为0.886（95％CI 0.788-0.984，p <0.001）。SUVmax降低超过83.0％的29名患者（63.0％）的中位PFS为34个月。PFS中位数为17（37。0％）ΔSUVmax<83.0％的患者为9个月。这种差异是显着的（p <0.001）。多恩评分（DS）和ΔSUVmax判断的阳性的科恩kappa系数为0.752（95％CI 0.592-0.992，p <0.001），表明具有很强的一致性。多因素分析表明，iPET2的ΔSUVmax小于诊断时SUVmax的83.0％是预测PFS的独立因素[HR = 11.339，95％CI 2.485-51.742，p = 0.002]。ΔSUVmax<83.0％的敏感性，特异性，阳性预测值，阴性预测值和准确性分别为84.6％，81.8％，67.7％，93.1％和82.6％，与DS的61.5％，87.9％相似。 ，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。多恩评分（DS）和ΔSUVmax判断的阳性的科恩kappa系数为0.752（95％CI 0.592-0.992，p <0.001），表明具有很强的一致性。多因素分析表明，iPET2的ΔSUVmax小于诊断时SUVmax的83.0％是预测PFS的独立因素[HR = 11.339，95％CI 2.485-51.742，p = 0.002]。ΔSUVmax<83.0％的敏感性，特异性，阳性预测值，阴性预测值和准确性分别为84.6％，81.8％，67.7％，93.1％和82.6％，与DS的61.5％，87.9％相似。 ，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。多恩评分（DS）和ΔSUVmax判断的阳性的科恩kappa系数为0.752（95％CI 0.592-0.992，p <0.001），表明具有很强的一致性。多因素分析表明，iPET2的ΔSUVmax小于诊断时SUVmax的83.0％是预测PFS的独立因素[HR = 11.339，95％CI 2.485-51.742，p = 0.002]。ΔSUVmax<83.0％的敏感性，特异性，阳性预测值，阴性预测值和准确性分别为84.6％，81.8％，67.7％，93.1％和82.6％，与DS的61.5％，87.9％相似。 ，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。多因素分析表明，iPET2的ΔSUVmax小于诊断时SUVmax的83.0％是预测PFS的独立因素[HR = 11.339，95％CI 2.485-51.742，p = 0.002]。ΔSUVmax<83.0％的敏感性，特异性，阳性预测值，阴性预测值和准确性分别为84.6％，81.8％，67.7％，93.1％和82.6％，与DS的61.5％，87.9％相似。 ，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。多因素分析表明，iPET2的ΔSUVmax小于诊断时SUVmax的83.0％是预测PFS的独立因素[HR = 11.339，95％CI 2.485-51.742，p = 0.002]。ΔSUVmax<83.0％的敏感性，特异性，阳性预测值，阴性预测值和准确性分别为84.6％，81.8％，67.7％，93.1％和82.6％，与DS的61.5％，87.9％相似。 ，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。与DS相似，分别为61.5％，87.9％，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。与DS相似，分别为61.5％，87.9％，66.7％，85.3％和80.4％。iPET2的ΔSUVmax<83.0％有效预测ABVD治疗的CHL患者的预后。